Smith & Nephew PLC
LSE:SN

Watchlist Manager
Smith & Nephew PLC Logo
Smith & Nephew PLC
LSE:SN
Watchlist
Price: 986.8 GBX 1.11% Market Closed
Market Cap: 8.6B GBX
Have any thoughts about
Smith & Nephew PLC?
Write Note

Operating Margin
Smith & Nephew PLC

12.3%
Current
13%
Average
4.2%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
12.3%
=
Operating Profit
696m
/
Revenue
5.6B

Operating Margin Across Competitors

Country UK
Market Cap 8.6B GBP
Operating Margin
12%
Country US
Market Cap 204.9B USD
Operating Margin
17%
Country US
Market Cap 195.2B USD
Operating Margin
26%
Country US
Market Cap 146.7B USD
Operating Margin
22%
Country US
Market Cap 132.6B USD
Operating Margin
18%
Country IE
Market Cap 110.6B USD
Operating Margin
19%
Country US
Market Cap 64.7B USD
Operating Margin
14%
Country DE
Market Cap 55.6B EUR
Operating Margin
12%
Country CN
Market Cap 319.2B CNY
Operating Margin
37%
Country US
Market Cap 41.6B USD
Operating Margin
28%
Country US
Market Cap 37.7B USD
Operating Margin
13%
No Stocks Found

Smith & Nephew PLC
Glance View

Market Cap
8.6B GBX
Industry
Health Care

Smith & Nephew PLC has a rich history dating back to 1856, evolving from a small medical supplies company in the UK to a prominent global player in the medical technology industry. The company specializes in advanced wound management, surgical devices, and orthopedic reconstruction, driven by a mission to restore people’s bodies and health, enabling them to live life to the fullest. As an investor, you’ll find that Smith & Nephew stands out for its commitment to innovation, consistently investing a significant portion of its revenue into research and development. This dedication results in a robust pipeline of cutting-edge products, such as its highly regarded advanced wound care solutions and knee and hip reconstruction devices. The company’s strategic focus on emerging markets and partnerships with healthcare providers positions it well for sustainable growth amid shifts in the global healthcare landscape. Navigating the complexities of the healthcare sector, Smith & Nephew demonstrates resilience through its diversified product range and broad geographic presence, generating revenue from both developed and developing markets. The company has been enhancing its operational efficiency, improved profit margins, and reduced costs, which resonate well with value investors seeking financially sound opportunities. Furthermore, the company’s commitment to environmental, social, and governance (ESG) principles may appeal to socially conscious investors. As Smith & Nephew continues to leverage technological advancements and respond to the evolving needs of healthcare systems, its story remains compelling – offering not just potential financial returns but also a commitment to improving patient outcomes and enhancing the quality of life around the globe.

SN Intrinsic Value
1 458.57 GBX
Undervaluation 32%
Intrinsic Value
Price

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
12.3%
=
Operating Profit
696m
/
Revenue
5.6B
What is the Operating Margin of Smith & Nephew PLC?

Based on Smith & Nephew PLC's most recent financial statements, the company has Operating Margin of 12.3%.